Cadila Healthcare shines on launching pressurised metered dose inhaler

A global innovation-driven pharmaceutical company, Zydus Cadila announced on Thursday that it is launching Forglyn pMDI, India’s first pressurised metered dose inhaler (pMDI) along with a combination of a long-acting muscarinic antagonist (LAMA) and long-acting beta-agonist (LABA). Reacting to the news, the share of the company rose nearly 3 per cent on BSE.

Forglyn pMDI will be used to treat patients suffering from chronic obstructive pulmonary disease (COPD) in India. It is developed in-house using Zydus’ innovations in formulation technology and is priced at Rs 495 per pack. The single inhalation of the two drugs would result in a synergetic effect and will be better adherence to the treatment.  

The technological process employed by the company for the manufacturing of this product is simple, affordable, and scalable. Besides, the company also filed a patent application for the innovative process of this product.

The company stands third in the respiratory market. It has more than 100 brands/SKUs in the therapeutic area of asthma, COPD, idiopathic pulmonary fibrosis (IPF), and cough & cold.

At 3.13 pm today, the share of Cadila Healthcare was trading at 5.51 per cent higher than its previous close at Rs 435.60. The share has an intraday high of Rs 434.7 on BSE.